Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Restructuring Costs (2019)

Seres Therapeutics (MCRB) has disclosed Restructuring Costs for 1 consecutive years, with $1.5 million as the latest value for Q1 2019.

  • Quarterly Restructuring Costs changed N/A to $1.5 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2019, changed N/A year-over-year, with the annual reading at $1.5 million for FY2019, N/A changed from the prior year.
  • Restructuring Costs hit $1.5 million in Q1 2019 for Seres Therapeutics.
  • In the past five years, Restructuring Costs ranged from a high of $1.5 million in Q1 2019 to a low of $1.5 million in Q1 2019.